Trial Profile
Examination of virological response and predictive factors in Elbasvir/Grazoprevir combination therapy for genotype1 infected chronic hepatitis C patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2021
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 29 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 05 Oct 2017 New trial record